Evidence map›Paper›PMID 40007771›Full record

ArticleFrontiers in artificial intelligence2024

One size fits all: Enhanced zero-shot text classification for patient listening on social media.

Veton Matoshi, Maria Carmela De Vuono, Roberto Gaspari, Mark Kröll, Michael Jantscher, Sara Lucia Nicolardi, Giuseppe Mazzola, Manuela Rauch, Vedran Sabol, Eileen Salhofer and 1 more

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Veton MatoshiIndependent Researcher, Graz, Austria.
Maria Carmela De VuonoKnow Center Research GmbH, Graz, Austria.
Roberto GaspariKnow Center Research GmbH, Graz, Austria.
Mark KröllChiesi Farmaceutici S.p.A, Parma, Italy.
Michael JantscherChiesi Farmaceutici S.p.A, Parma, Italy.
Sara Lucia NicolardiKnow Center Research GmbH, Graz, Austria.
Giuseppe MazzolaKnow Center Research GmbH, Graz, Austria.
Manuela RauchChiesi Farmaceutici S.p.A, Parma, Italy.
Vedran SabolChiesi Farmaceutici S.p.A, Parma, Italy.
Eileen SalhoferChiesi Farmaceutici S.p.A, Parma, Italy.
Riccardo MarianiKnow Center Research GmbH, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-focused drug development (PFDD) represents a transformative approach that is reshaping the pharmaceutical landscape by centering on patients throughout the drug development process. Recent advancements in Artificial Intelligence (AI), especially in Natural Language Processing (NLP), have enabled the analysis of vast social media datasets, also called Social Media Listening (SML), providing insights not only into patient perspectives but also into those of other interest groups such as caregivers. In this method study, we propose an NLP framework that-given a particular disease-is designed to extract pertinent information related to three primary research topics: identification of interest groups, understanding of challenges, and assessing treatments and support systems. Leveraging external resources like ontologies and employing various NLP techniques, particularly zero-shot text classification, the presented framework yields initial meaningful insights into these research topics with minimal annotation effort.

Indexed as

named entity recognitionpatient centricpatient-focused drug developmentpatient’s perspectiverelation extractionsocial media listeningzero-shot classification

Identifiers

PMID40007771
PMCPMC11850375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.